Allergy Immunotherapy Market

The global Allergy Immunotherapy Market is valued at USD 1.92 Billion in 2024 and is projected to reach a value of USD 4.9 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8.95% between 2025 and 2035.

Premium Insights

Allergy is becoming a more significant issue, affecting as many as one in three people in developed countries. In the United States, 13% of children and 14% of adults suffer from allergic rhinitis, while in Europe, it affects 23% of adults. Additionally, 3.4% of children and 7.5% of adults in Europe experience general allergic reactions from Hymenoptera stings. Finding effective solutions is crucial because there are so many different types of allergies. Allergy immunotherapy is a promising approach to tackling this problem. In the United States, 8% of children have a clear history of food allergy, with 2% specifically allergic to peanuts, highlighting the urgency for targeted interventions. By using immunotherapy to address specific allergies, it can greatly enhance the quality of life for a significant portion of the population.

• In European countries, ready-to-use alum-precipitated and/or further modified aeroallergens have become prevalent in clinical practice. Conversely, practitioners in the United States have predominantly favored using aqueous or glycerinated products for allergy immunotherapy.
• Europe generated more than 63.4% of revenue share in 2022.
• The Asia Pacific region is expected to grow at the quickest rate from 2023 to 2030.
• The Subcutaneous Immunotherapy (SCIT) segment accounted for the most considerable market growth in 2022.
• The Allergic Rhinitis segment revealed the most significant market growth in 2022.
• The Institutional Sales segment accounts for the largest revenue share of 42.5% in 2022.

Economic Insights

The economic impact of Allergy Immunotherapy is enormous and affects various aspects of the economy in Europe. One major issue is the decrease in productivity and the increase in sick days taken by people with allergies. This puts a financial burden on businesses, the healthcare system, and the countrys overall economy. Allergy-related health problems also come with high costs, such as €3.6 billion per year spent on asthma medication and €4.3 billion per year on healthcare services. These expenses contribute to the already strained European economy. Additionally, there are indirect costs that add to the economic burden. Approximately 15% of the European population requires long-term treatment for allergies and/or asthma, especially children and young individuals. This leads to prolonged medical interventions, which further strain the economy. By effectively addressing these economic implications through Allergy Immunotherapy, not only can individual health improve, but it also has the potential to relieve the financial strain on the nation and businesses.

Top Market Trends

• The rising incidence of allergies, including allergic rhinitis, asthma, and food allergies, drives the demand for allergy immunotherapy. According to the World Allergy Organization, the prevalence of allergic diseases continuously increases globally, leading to a larger patient pool for allergy immunotherapy.
• As healthcare continues to shift towards personalized approaches, the demand for customized allergy immunotherapy is rising. Patients and physicians increasingly opt for customized immunotherapy treatments tailored to individual needs, targeting specific allergens and medical conditions.
• Technological advancements have led to the development of innovative formulations for allergy immunotherapy. For instance, introducing allergy immunotherapy tablets for sublingual administration has improved patient compliance and reduced the need for frequent clinic visits. These developments would fuel market expansion.
• The allergy immunotherapy market is witnessing significant research and development efforts to enhance treatment efficacy and patient outcomes. This includes the development of new allergen extracts, innovative delivery systems, and adjuvants to improve immunotherapy effectiveness. These advancements are likely to expand the market in the coming years.

Market Segmentation

The Global Allergy Immunotherapy Market is segregated into the below-mentioned segments as:

{{Segmentation_Ext}}

Based on Type

Subcutaneous Immunotherapy (SCIT) holds the largest share

Subcutaneous Immunotherapy (SCIT) was dominating the market for allergy treatment in 2022 due to its effectiveness compared to SLIT therapy. There is a growing focus on SCIT, with companies introducing subcutaneous products and forming partnerships to expand their presence in the market. It is expected that the distribution and adoption of SCIT will increase. For instance, Stallergenes Greer reintroduced their SCIT product, Alustal, in Spain and Italy after resuming production in France. In addition, the approval and launch of various SLIT products are also expected to contribute to the expansion of the market. One noteworthy development is the U.S. FDA approval of ALKs sublingual tablet, ODACTRA, in January 2023. This tablet is designed to treat house dust mite-induced allergic rhinitis. This approval reflects the dynamic nature of the allergy immunotherapy market and is likely to impact market growth positively.

Based on Allergy Type

Allergic Rhinitis Forecast to Dominate the Market

The allergic rhinitis segment is predicted to gain dominance in 2022 due to the increasing number of cases worldwide. A study published in NCBI in 2022 reveals that the prevalence of allergic rhinitis is as high as 30% globally, with approximately 15% of cases diagnosed by physicians. The release of innovative products by major competitors that target allergic rhinitis specifically and use various forms of therapy is anticipated to drive market expansion. In April 2021, ALK expanded the FDA approval for Ragwitek, a short ragweed pollen allergen extract, to include treatment for children and adolescents aged five years and older who have allergic rhinitis caused by short ragweed pollen.

Based on the Distribution Channel

Institutional Sales Expected to Account for the Largest Market Share

Institutional sales have the potential to generate the most revenue. This is because government and semi-government hospitals heavily rely on these sales for treatments, mainly due to their cost-effectiveness. Government hospitals in developed economies also provide reimbursements and supportive policies, further boosting institutional sales. The dominance of institutional sales in the market can be attributed to various factors, including established players with strong distribution networks, high entry barriers, and regulations that favor institutional sales. The institutional sales segment is exceptionally skilled at handling the complex logistical and regulatory challenges of delivering allergy immunotherapy products. This includes managing complicated supply chains, adhering to regulatory standards, and ensuring high product quality and safety levels. The ability of the institutional sales channel to navigate these challenges contributes to its prominence in the market and makes it a significant contributor to overall revenue generation.

Based on Region

Europe Expected to Lead the Market in the Forecast Period

Europe emerged as a dominant region in the allergy immunotherapy market in 2022. It is expected to continue leading the market in the future. The regions growth is driven by the rising prevalence of allergies, which has prompted governments and companies to develop and introduce allergy immunotherapy products. There is a particular focus on expanding product offerings to address various allergies, including food and insect allergies. The availability of proper reimbursement for therapy also supports market growth in Europe. For example, Stellargenes Greer launched a sublingual immunotherapy tablet called Orylmyte in Belgium in November 2021, showcasing the markets momentum. The United Kingdoms allergy immunotherapy market is experiencing potential growth due to the increasing prevalence of allergies such as asthma, rhinitis, and conjunctivitis. With approximately 20% of the UK population suffering from one or more allergy disorders, the country exhibits one of the highest global prevalence rates.

Competitive Landscape

Major companies contribute to the

allergy

The players in the global Allergy Immunotherapy market include Merck KGaA (Germany) among others.

Recent Market Developments

• In October 2023, ALK-Abelló A/S announced top-line results from a Phase 3 pediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. The tree tablet is marketed as ITULAZAX® in Europe and as ITULATEK® in Canada for patients aged 18 to 65.
• In September 2023, Stallergenes Greer, a leading global healthcare company that specializes in allergen immunotherapy (AIT), and Nestlé has agreed to harness the peanut allergy oral immunotherapy treatment Palforzia®.
• In November 2022, Aimmune Therapeutics, Inc., a Nestlé Health Science company presented the first results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study.

Segmentation of the Global Allergy Immunotherapy Market